Status:
RECRUITING
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
Lead Sponsor:
Fudan University
Conditions:
Pancreatic Neoplasms
Eligibility:
All Genders
14-80 years
Phase:
PHASE2
Brief Summary
Tamoxifen for Solid Pseudopapillary Tumor of the Pancreas
Detailed Description
Solid pseudopapillary tumor of the pancreas (SPTP) is a rare neoplasm, predominantly affecting young females, with unclear pathogenesis and hormonal receptor (estrogen/progesterone receptor) expressio...
Eligibility Criteria
Inclusion
- Age 14-80 years.
- Histologically confirmed advanced SPTP with ER/PR+.
- Advanced disease:
- Unresectable primary tumor or distant metastasis (liver, lung, peritoneum, etc.).
- Recurrent or refractory after prior surgery/systemic therapy.
- ≥1 measurable lesion.
- ECOG performance status 0-2.
- Life expectancy ≥1 month.
- Able to comply with study visits and oral medication.
Exclusion
- Non-SPTP pathology.
- Active gastrointestinal inflammation/infection (e.g., pancreatitis).
- Pregnancy/lactation.
- Severe organ dysfunction (renal, cardiac, hepatic, or pulmonary).
- Uncontrolled comorbidities (e.g., CNS disorders, unstable angina).
- Conditions compromising patient safety or data integrity.
Key Trial Info
Start Date :
March 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06914674
Start Date
March 20 2025
End Date
February 28 2028
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Cancer Center
Shanghai, China, 200032